Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 214

Doctor Anywhere locates $27m

IHH Healthcare participated in a series B round that boosted the care provider's capital base to more than $40m.

Apr 1, 2020

Hualan Biological Vaccines hooks $292m

Hillhouse Capital and Chen Yi Investment are making a secondary investment in the Hualan Biological Engineering spinoff which is now valued at more than $1.9bn.

Mar 31, 2020

Avail puts $15m in its eyeline

Avail Medsystems, a remote medical device startup which counts Baidu Ventures as an investor, has captured $15m in new funding.

Mar 31, 2020

GSK displays Lyell Immunopharma investment

The corporate owned a 15% stake in immunotherapy developer Lyell, which recently raised $493m, with a fair value of $203m as of the end of 2019.

Mar 30, 2020

Shiratronics sharpens series A to $36m

Shiratronics added $3m from Breakout Ventures to a LivaNova-backed round that will support clinical development of its neuromodulation-based migraine treatment.

Mar 30, 2020

Redpin receives series A funding

Takeda Ventures and Alexandria Venture Investments contributed to the $15.5m first close of the gene therapy developer's series A round.

Mar 30, 2020

SutroVax sorts out $110m series D

Roche Venture Fund returned to help SutroVax, a developer of vaccines for a range of deadly infectious diseases, push its overall funding past $280m.

Mar 27, 2020

Welmo swells series B round

Tepco Power Grid helped the specialised care software developer take its latest round, which already included Line, Mixi, Aioi Nissay Dowa, Akatsuki, Global Kids and Konica Minolta, to $14.3m.

Mar 27, 2020

Kallyope digests $112m in series C round

Illumina Ventures was among the returning investors for the round that will help Kallyope prepare a weight loss treatment for clinical trials.

Mar 26, 2020

Regenacy regulates $30m series A

Viva Biotech contributed to a round that will help Regenacy Pharmaceuticals push its diabetic peripheral neuropathy candidate into phase 2 trials.

Mar 26, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here